{
    "clinical_study": {
        "@rank": "36833", 
        "arm_group": [
            {
                "arm_group_label": "sonifilan", 
                "arm_group_type": "Experimental", 
                "description": "Group who get sonifilan"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "No Sonifilan administered"
            }
        ], 
        "brief_summary": {
            "textblock": "The impact of sonifilan on the quality of life in patients with cervical cancer during\n      radiation or chemoradiation therapy\n\n        1. Primary endpoint : Quality of life\n\n        2. Secondary endpoint : complications related to Sonifilan, treatment effect of Sonifilan"
        }, 
        "brief_title": "Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Study design Prospective randomized controlled trial\n\n      Study period Protocol registration approval date - may/31/2016\n\n      Study drug Sonifilan(Sizofiran)\n\n      Study population\n\n        1. Cervical cancer FIGO stage IA2-IVA patients will be participated.\n\n        2. Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma\n\n        3. age 20-75 year\n\n      Treatment Fron the day of radiation therapy started, Sonifilan 20mg, 1amp IM/week for 8weeks\n\n      Concurrent therapy Chemo & radiation therapy\n\n        1. Cisplatin 40mg/m2, day 1, 8, 15, 2, 29, 36\n\n        2. External whole pelvic irradiation 3000-3500 cGy / 6 fractions in high dose rate\n\n      Assessment\n\n        1. Pre-study assessment (within 4weeks before participation) a medical history b informed\n           consent c ID number assignment d life quality assessment - fill out EORTC QOQ-C30,\n           CX24, SF-36, FSFI e basic information collect\n\n        2. On-study assessment (during study) a complication check b life quality assessment -\n           fill out EORTC QOQ-C30, CX24, SF-36, FSFI\n\n      3. Post-study assessment (1week after study finished) a MRI b PAP smear c HPV test d life\n      quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI\n\n      4 Follow-up assessment (every 3 month for 1 year) a Pelvic exam b PAP smear c HPV test d MRI\n      (if needed) e PET (if needed) f life quality assessment - fill out EORTC QOQ-C30, CX24,\n      SF-36, FSFI 93, 6, 12, 24 month after study finished)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cervical cancer FIGO stage IA2 - IVA\n\n          -  Histologic type : SCC, Adenocarcinoma, Adenosquamous carcinoma\n\n          -  GOG performance status 0-2\n\n        Exclusion Criteria:\n\n          -  past radiation therapy history\n\n          -  Neuroendocrine carcinoma\n\n          -  concurrent other cancer\n\n          -  uncontrolled medical disease\n\n          -  ulcerative disease history\n\n          -  current pregnancy and lactation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926821", 
            "org_study_id": "SIZO2013"
        }, 
        "intervention": {
            "arm_group_label": "sonifilan", 
            "description": "Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times", 
            "intervention_name": "Sonifilan", 
            "intervention_type": "Drug", 
            "other_name": [
                "sizofiran inj 20mg", 
                "Code : XSISO"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sizofiran"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "JongHyeokKim"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer", 
        "overall_contact": {
            "email": "bronx46@hotmail.com", 
            "last_name": "WooSuk Han, Master", 
            "phone": "82-10-4818-9296"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Cneter", 
            "last_name": "jongHyeok Kim, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "life quality assessment by filling out EORTC QOQ-C30, CX24, SF-36, FSFI pre-/on-/post-study", 
            "measure": "Quality of life", 
            "safety_issue": "Yes", 
            "time_frame": "3 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926821"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Jong-Hyeok Kim", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Complications of drug, treatment effects", 
            "safety_issue": "Yes", 
            "time_frame": "3 year"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}